

Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity

SIYUAN CHEN¹, YALI WANG¹, WENWEN RUAN¹, XIAOMIN WANG² and CHAO PAN¹

Departments of ¹Pathology and ²Hepatobiliary Surgery, Digestive Diseases Institute, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, P.R. China

Received December 28, 2013; Accepted August 7, 2014

DOI: 10.3892/ol.2014.2521

Abstract. The aim of the present study was to evaluate whether downregulation of extracellular signal-regulated kinase 1/2 (ERK1/2) is involved in conventional reversal methods and whether the inhibitors of the ERK signaling pathway reverse multidrug resistance (MDR) in hepatocellular carcinoma (HCC) cells. The sensitivities of SMMC7721 and BEL7402, and the MDR SMMC7721/Adriamycin (ADM) and BEL7402/ADM HCC cell lines to ADM were evaluated by CellTiter-Glo[®] luminescent cell viability assay through calculating the half maximal inhibitory concentration (IC₅₀) of ADM. In addition, the expression levels of ERK1/2 and phosphorylated (p)ERK1/2 were determined by western blot analysis subsequent to treatment of the cells with PD98059, an MEK inhibitor, or sorafenib, a multikinase inhibitor. The results revealed that the ADM IC₅₀ for the SMMC7721/ADM cells was 16.44 times higher than that of the SMMC7721 cells (P<0.05), and the ADM IC₅₀ for the BEL7402/ADM cells was 20.34 times higher than that of the BEL7402 cells (P<0.05). Following treatment with PD98059 or sorafenib, the expression levels of pERK1/2 in the MDR cells decreased in a dose-dependent manner. Subsequent to treatment with 5 μ M PD98059, the ADM IC₅₀ values for the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.8 \pm 0.056 and 1.583 \pm 0.284 μ g/ml, respectively. Following treatment with 2.5 μ M sorafenib, the ADM IC₅₀ values for the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.264 \pm 0.049 and 1.099 \pm 0.135 μ g/ml, respectively. Subsequent to incubation with 4 μ g/ml cyclosporine A (CsA),

a classic MDR reversal agent, the ADM IC₅₀ values in the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.349 \pm 0.023 and 0.427 \pm 0.039 μ g/ml, respectively. CsA treatment also increased the expression levels of pERK1/2 without affecting the total ERK1/2 levels. Therefore, the inhibition of ERK signaling pathway activity may be an important method to reverse the MDR of HCC cells, but is not unique.

Introduction

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide, with high recurrence and a low five-year survival rate (1). Thus far, excision remains the most significant method in the comprehensive treatment of HCC. However, resection of the tumor using surgery is difficult in the majority of cases of HCC, since >80% patients are suffering from advanced or unresectable diseases at the final diagnosis (2,3). Even following successful resection, the recurrence may be as high as 50% after two years (4). Chemotherapy is used as an adjuvant post-operative treatment, with the aim of reducing tumor recurrence. However, conventional systemic chemotherapy has shown only minor effectiveness with response rates of <10%, due to the intrinsic or acquired drug resistance caused by multidrug resistance (MDR) (4,5). The mechanisms of drug resistance are heterogeneous and include increased anticancer agent efflux by adenosine triphosphate (ATP)-binding cassette proteins, apoptotic inhibition, DNA repair activation and detoxifying system enhancement (6). Although numerous MDR reversal agents have been reported, the clinical application of these drugs is limited due to side-effects or toxicity that are unacceptable at the effective dose (7). Thus, identifying MDR reversal agents with high reversal activity and low toxicity is important.

Recently, evidence has accumulated demonstrating that the activation of the mitogen-activated protein kinase (MAPK) signaling pathway is associated with MDR in multiple types of tumors and that this signaling pathway has a predominant role in various cellular processes, including proliferation, differentiation, apoptosis, angiogenesis and migration (8-13). The MAPK group includes four distinct signaling cascades, which are known by the corresponding MAPK tier component:

Correspondence to: Professor Chao Pan, Department of Pathology, Zhongshan Hospital, Xiamen University, 1 South Hubin Road, Xiamen, Fujian 361004, P.R. China
E-mail: panchao123a@126.com

Key words: hepatocellular carcinoma, multidrug resistance, reverse, extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway

Extracellular signal-regulated kinase 1 and 2 (ERK1/2) (14-16); c-Jun N-terminal kinase 1 to 3 (17,18); p38 MAPK α , β , γ and δ (p38 α - δ) (19-22); and ERK5, also known as Big MAPK (23,24). The ERK1/2 cascade, which has been the most widely analyzed module in the MAPK signaling pathways, transmits predominantly mitogenic signals. The activation of the ERK1/2 signaling pathway is induced by guanosine 5'-triphosphate loading of Ras at the plasma membrane, which is followed by sequential activation of a series of protein kinases, including a member of the Raf family (such as Raf-1), MAPK or ERK kinase (MEK) 1/2, then ERK1 or ERK2 (25). Our previous study demonstrated that ERK1/2 is highly expressed in several HCC cells with MDR (26). The aim of the present study was to analyze whether the ERK/MAPK inhibitors reverse MDR in HCC cells. Furthermore, one classical MDR reversal agent, cyclosporine A (CsA), was selected to examine whether downregulation of ERK/MAPK signaling pathway activity is involved in the reversal mechanism of traditional methods, such as the inhibition of p-gp.

Materials and methods

Compounds. Sorafenib (Nexavar, BAY 43-9006), a multikinase inhibitor [for vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma (RAF) kinases], was manufactured by Bayer Pharmaceuticals (West Haven, CT, USA). PD98059, a MEK inhibitor, was purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). CsA was obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). The compounds were dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) and diluted with RPMI 1640 to obtain a final DMSO concentration of 0.1% for the *in vitro* experiments. DMSO was subsequently added to the cell cultures at 0.1% (v/v) as a solvent control.

Cell lines and cell culture. The SMMC7721 and BEL7402 human HCC cell lines were purchased from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Science, Chinese Academy of Sciences (Shanghai, China). The SMMC7721 and BEL7402 cells were cultured with RPMI-1640 (HyClone Laboratories, Inc., Logan, UT, USA). The medium was supplemented with 10% calf serum, 100 IU/ml penicillin and 100 μ g/ml streptomycin (all HyClone), and maintained at 37°C in a humidified atmosphere containing 50 ml/l CO₂ and 950 ml/l air. To establish SMMC7721/Adriamycin (ADM) and BEL7402/ADM MDR cells, ADM (Shanghai Sheng Gong Biological Engineering Co., Ltd., Shanghai, China) was added to SMMC7721 and BEL7402 cells, respectively, at increasing stepwise concentrations between 1 and 5 mg/l. Resistant cells were selected by removing the non-resistant dead cells. MDR was maintained by culturing the cells with 5 mg/l ADM; the MDR cells were termed the SMMC7721/ADM and BEL7402/ADM cells. This study was approved by the ethics committee of the Affiliated Hospital of Xiamen University (Xiamen, China).

CellTiter-Glo[®] luminescent cell viability assay. The cells were plated at 3,000 cells per well in 96-well microtiter plates and incubated overnight at 37°C in a humidified incubator

containing 5% CO₂. On the following days, the corresponding compounds were added to the wells and the cultures were incubated for an additional 48 h. To investigate the drug resistance of MDR cells, the parental cells and MDR cells were exposed to various concentrations of ADM (0, 0.25, 1, 4, 16 or 64 μ g/ml). A combination of various concentrations of ADM (0, 0.25, 1, 4, 16 or 64 μ g/ml) and sorafenib (2.5 μ M), PD98059 (5 μ M) or CsA (4 μ g/ml) were added to the experimental groups. Cell viability was determined using the CellTiter-Glo luminescent cell viability kit from Promega Corporation (Madison, WI, USA) according to the manufacturer's instructions. This method was based on the measurement of ATP production in the cells, proportional to the number of viable cells, detected by luciferin-luciferase reaction. The cell proliferation inhibition rate was calculated by the following formula: Cell proliferation inhibition rate = (1 - relative luminescence of the experimental group / relative luminescence of the control group) \times 100. All experiments were repeated at least three times and the average values were used as the final results. The half maximal inhibitory concentration (IC₅₀) value, which signifies 50% cell growth inhibition compared with the control, was calculated by non-linear regression analysis with GraphPad Prism version 5.0 software (GraphPad Software, Inc., San Diego, CA, USA), according to the results of at least three independent experiments, with four replicates of each cell line per experiment. The resistance index (RI) and reversal fold were calculated according to the following formulae: RI = (IC₅₀ of MDR cells) / (IC₅₀ of parental cells); and reversal fold = (IC₅₀ of MDR cells) / (IC₅₀ of MDR cells following reversal).

Western blot analysis. The cells were cultured in culture medium until 60-70% confluence was reached. DMSO and PD98059 (2.5, 5, 10 or 20 μ M) were added to the control and experimental groups, which were incubated for 1 h. Sorafenib (2.5, 5 or 10 μ M) or CsA (0.25, 1, 4, or 16 μ g/ml) were then added to the experimental groups, and DMSO was added to the control groups. The cells were then incubated for 24 h. Adherent cells were washed with cold phosphate-buffered saline and lysed directly in the dish for 20 min on ice with cell lysis buffer [containing 150 mmol/l NaCl, 50 mmol/l Tris-HCl (pH 7.4), 2 mmol/l EDTA, 1% NP-40, protease inhibitor cocktail and phosphatase inhibitor cocktail; Applygen Technologies Inc., Beijing, China]. The lysates were then incubated at 4°C for 20 min and centrifuged for 10 min at 12,000 \times g. The protein levels in the extracts were quantified using a bicinchoninic acid assay (Pierce Biotechnology, Inc., Rockford, IL, USA). Subsequently, the protein was denatured in a lithium dodecyl sulfate sample buffer for 5 min at 105°C. Equal quantities of total protein (20 μ g per lane) were resolved on 12% polyacrylamide gels using standard sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane (0.45 μ m, Millipore, Billerica, MA, USA). The membranes were blocked with 5% dry milk in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBST) for 1 h at room temperature and incubated overnight at 4°C with the following primary antibodies: monoclonal rabbit anti-human, -mouse, -rat, -hamster, -monkey, -mink, -D. melanogaster, -zebrafish, -bovine, -dog, -pig, -S. cerevisiae, phosphorylated (p)ERK1/2

(1:2,000; Thr202/Tyr204; Cell Signaling Technology, Inc.), polyclonal rabbit anti-human, -mouse, -rat, -equine, -canine, -bovine, -porcine and -avian, ERK1/2 (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), polyclonal rabbit anti-human, -mouse, -rat and -baboon, GAPDH (1:1,000; Epitomics, Inc., Burlingame, CA, USA). Following incubation with the respective primary antibodies, the membranes were washed three times for 5 min in TBST. The membranes were then exposed to horseradish peroxidase-conjugated monoclonal goat anti-rabbit immunoglobulin G (1:1,000; Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou, China) for 1 h at room temperature. Following incubation with the secondary antibodies, the membranes were washed three times for 5 min in TBST. The signal was detected with an Enhanced Chemiluminescence Western Blotting Detection kit (Applygen Technologies Inc.). The results are presented as the ratio of the density of the target protein to that of GAPDH. Each experiment was repeated at least three times and the final results are shown as the mean values.

Statistical analysis. Statistical analysis was performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA) and data are shown as the mean \pm standard deviation. Student's t-test and a one-way analysis of variance were used for the statistical analyses. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

SMMC7721/ADM and BEL7402/ADM cells exhibit stable drug resistance. The ADM IC₅₀ values of the SMMC7721 and SMMC7721/ADM cells were 0.089 ± 0.026 and 1.463 ± 0.168 $\mu\text{g/ml}$, respectively, and the RI of the SMMC7721/ADM cells was 16.44. The ADM IC₅₀ values of the BEL7402 and BEL7402/ADM cells were 0.161 ± 0.039 $\mu\text{g/ml}$ and 3.266 ± 0.271 $\mu\text{g/ml}$, respectively, and the RI of the BEL7402/ADM cells was 20.34. The results are shown in Fig. 1 and Table I. The data show that the ADM sensitivities of the SMMC7721/ADM and BEL7402/ADM cells were significantly lower than those of the corresponding non-resistant parent cells ($P = 0.000$), which indicates that the SMMC7721/ADM and BEL7402/ADM cells exhibited stable chemoresistance.

PD98059 and sorafenib inhibit ERK/MAPK signaling pathway activity in SMMC7721/ADM and BEL7402/ADM cells. Subsequent to 1 h of treatment with PD98059, the pERK1/2 expression rates (% of control) in the SMMC7721/ADM (Fig. 2A) and BEL7402/ADM (Fig. 2B) cells were down-regulated in a dose-dependent manner. At concentrations of 2.5, 5, 10 and 20 μM , the rates declined to 97.43 ± 1.51 , 70.53 ± 4.23 , 62.33 ± 3.34 and $25.79 \pm 5.33\%$, respectively, in the SMMC7721/ADM cells, and to 91.01 ± 2.27 , 86.31 ± 6.54 , 84.54 ± 4.98 and $55.53 \pm 3.75\%$, respectively, in the BEL7402/ADM cells (Fig. 2E). Following 24 h of treatment with sorafenib at these same concentrations, pERK expression was again inhibited in a concentration-dependent manner (Fig. 2C and D). At concentrations of 2.5, 5 and 10 μM sorafenib, the pERK1/2 expression rates were reduced to 91.71 ± 3 , 50.41 ± 2.3 and $42.76 \pm 2.6\%$, respectively, in the SMMC7721/ADM cells, and to 88.45 ± 3.1 , 68.79 ± 2.9

Table I. ADM IC₅₀ in SMMC7721, SMMC7721/ADM, BEL7402 and BEL7402/ADM cells.

Cell line	ADM IC ₅₀ , $\mu\text{g/ml}$	Resistance index
SMMC7721	0.089 ± 0.006	
SMMC7721/ADM	1.463 ± 0.068	16.44 ^a
BEL7402	0.161 ± 0.03	
BEL7402/ADM	3.266 ± 0.072	20.34 ^b

^a $P < 0.05$ vs. SMMC7721; ^b $P < 0.05$ vs. BEL7402. IC₅₀, half maximal inhibitory concentration; ADM, Adriamycin.

Table II. ADM IC₅₀ in hepatocellular carcinoma multi-drug-resistant cells treated with PD98059, sorafenib and CsA.

Cell line/treatment	ADM IC ₅₀ , $\mu\text{g/ml}$	Reverse-fold
SMMC7721/ADM	1.463 ± 0.168	
SMMC7721/ADM+PD98059	0.800 ± 0.056	1.83 ^a
SMMC7721/ADM+sorafenib	0.264 ± 0.049	5.54 ^a
SMMC7721/ADM+CsA	0.349 ± 0.023	4.19 ^a
BEL7402/ADM	3.266 ± 0.271	
BEL7402/ADM+PD98059	1.583 ± 0.284	2.06 ^b
BEL7402/ADM+sorafenib	1.099 ± 0.135	2.97 ^b
BEL7402/ADM+CsA	0.427 ± 0.039	7.65 ^b

^a $P < 0.05$ vs. SMMC7721/ADM; ^b $P < 0.05$ vs. BEL7402/ADM. IC₅₀, half maximal inhibitory concentration; ; CsA, cyclosporine A; ADM, Adriamycin.

and $31.28 \pm 3.3\%$, respectively, in the BEL7402/ADM cells (Fig. 2F).

PD98059 and sorafenib increase the sensitivity of SMMC7721/ADM and BEL7402/ADM cells to ADM. Subsequent to 72 h of treatment, sorafenib inhibited MDR cell proliferation in a dose-dependent manner. When the drug concentration was 2.5 μM , the cell inhibition rates were $< 5\%$, at 4.35 and 1.84% for the SMMC7721/ADM and BEL7402/ADM cells, respectively. Thus, 2.5 μM was selected to be the concentration of sorafenib used for MDR reversal. Similarly, when the concentration of PD98059 was 5 μM , the cell inhibition rates for SMMC7721/ADM and BEL7402/ADM cells were 3.78 and 1.21%, respectively; therefore, 5 μM was selected as the reversal concentration of PD98059. The cell proliferation inhibition rates in the cells treated with a combination of ADM plus PD98059 or sorafenib were higher than those treated with ADM only (Fig. 3A and B). When 5 μM PD98059 was added, the ADM IC₅₀ values of the SMMC7721/ADM and BEL7402/ADM cells were 0.8 ± 0.056 and 1.583 ± 0.284 $\mu\text{g/ml}$, respectively. Furthermore, the reverse fold values were 1.83 in the SMMC7721/ADM cells and 2.06 in the BEL7402/ADM cells. When treated with 2.5 μM sorafenib, the ADM IC₅₀ values of the SMMC7721/ADM and BEL7402/ADM cells were 0.264 ± 0.049 and 1.099 ± 0.135 $\mu\text{g/ml}$,




Figure 1. Increased drug resistance of SMMC7721/Adriamycin (ADM) and BEL7402/ADM cells to the cytotoxic drug, ADM, compared with that of SMMC7721 and BEL7402 cells. (A) The SMMC7721 and SMMC7721/ADM cells were incubated with 0, 0.25, 1, 4, 16 or 64 $\mu\text{g/ml}$ ADM for 48 h. (B) The BEL7402 and BEL7402/ADM cells were also incubated with 0, 0.25, 1, 4, 16 or 64 $\mu\text{g/ml}$ ADM for 48 h. At the end of incubation, the cell survival rates were determined by CellTiter-Glo[®] luminescent cell viability assay and the proliferation inhibition rate was calculated. Results are reported as the mean \pm standard deviation of three independent experiments performed in five replicates.




Figure 2. PD98059 and sorafenib inhibit the extracellular signal-regulated kinase (ERK) signaling pathway activity of SMMC7721/Adriamycin (ADM) and BEL7402/ADM multidrug-resistant cells. (A) SMMC7721/ADM and (B) BEL7402/ADM cells were treated with the indicated concentrations of PD98059 for 1 h. (C) SMMC7721/ADM and (D) BEL7402/ADM cells were treated with the indicated concentrations of sorafenib for 24 h. Following treatment, whole cell protein extracts were prepared. Western blot analysis was performed using specific antibodies against the indicated proteins. (E and F) The phosphorylated (p)ERK expression rate was calculated from the pERK density, and the rate in each control group was set as the 100% baseline. Columns represent the mean of three experiments with six samples in each group; bars indicate standard error. * $P < 0.05$ vs. control. DMSO, dimethyl sulfoxide.

respectively. The reversal fold ADM resistance levels of the SMMC7721/ADM and BEL7402/ADM cells were 5.54-fold and 2.97-fold, respectively (Table II).

CsA enhances ADM sensitivity and upregulates ERK 1/2 phosphorylation in MDR HCC cells. As shown in Fig. 4A and B, the cell proliferation inhibition rate of the cells cultured with ADM plus CsA was significantly increased compared

with that of the cells cultured with ADM only ($P = 0.000$). When combined with 4 $\mu\text{g/ml}$ CsA, the ADM IC_{50} values of the SMMC7721/ADM and BEL7402/ADM cells were 0.349 ± 0.023 and 0.427 ± 0.039 $\mu\text{g/ml}$, respectively. The ADM resistance reversal levels of the SMMC7721/ADM and BEL7402/ADM cells were 4.19-fold and 7.65-fold, respectively (Table II). Following CsA treatment for 24 h, the pERK1/2 levels increased in a dose-dependent manner up to 4 $\mu\text{g/ml}$




Figure 3. PD98059 and sorafenib enhance the sensitivity of SMMC7721/Adriamycin (ADM) and BEL7402/ADM cells to ADM. (A) PD98059 and sorafenib increased the cell proliferation inhibition induced by ADM in the SMMC7721/ADM cells. (B) PD98059 and sorafenib increased the cell proliferation inhibition induced by ADM in the BEL7402/ADM cells. The cell proliferation viability was detected by the CellTiter-Glo luminescent[®] cell viability assay. Each value represents the average of four independent determinations with five replicates per experiment. Bars indicate standard error.




Figure 4. Cyclosporine A (CsA) enhances the sensitivity of cells to Adriamycin (ADM) and increases extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase signaling pathway activity in SMMC7721/ADM and BEL7402/ADM cells. (A and B) CsA increased the cell proliferation inhibition induced by ADM in the SMMC7721/ADM and BEL7402/ADM cells. The cell proliferation viability was detected by CellTiter-Glo[®] luminescent cell viability assay. Each value represents the average of four independent determinations with five replicates per experiment. Bars indicate standard error. (C) SMMC7721/ADM and (D) BEL7402/ADM cells were treated with the indicated concentrations of CsA for 24 h. Following treatment, whole cell protein extracts were prepared. Western blot analysis was performed using specific antibodies against the indicated proteins. (E) The phosphorylated (p)ERK expression rates were calculated from the pERK density, and the rate in each control group was set as the 100% baseline. Columns represent the mean of three experiment with six samples in each group; bars indicate standard error. *P<0.05 vs. control.

CsA and then declined at higher concentrations, but remained above the basal level. The total ERK1/2 levels were unchanged (Fig. 4C-E).

Discussion

HCC is the third most common cause of cancer mortality,

resulting in more than half a million fatalities annually worldwide (27,28). In addition to surgical intervention, systemic chemotherapy also has a significant role in HCC treatment, particularly for patients with advanced HCC (29). However, since traditional systemic chemotherapy has limited benefits in advanced-stage HCC patients due to MDR, novel approaches to overcome this resistance and offer patients tailored treatment strategies are urgently required (2,3). A number of MDR reversal agents have been developed, using the possible mechanisms being reported (30,31). However, toxicity has become the predominant obstacle in the wide application of these agents in clinical treatment (32). For instance, verapamil treatment induces cardiac toxicity and CsA exerts significant immunosuppressive effects and has renal toxicity. Therefore, identifying safe and efficient reversal agents is of vital importance for treating advanced-stage HCC patients.

The MAPK signaling pathway is known to mediate a number of cellular processes, including cell growth, differentiation, survival and apoptosis. Aside from these fundamental functions, MAPK has also been reported to be involved in the development of MDR, conferring imatinib resistance in acute lymphoblastic leukemia cells (33), vincristine resistance in gastric cancer cells (34) and anthracycline resistance in breast cancer cells (35).

Among the four MAPK signaling pathways, the ERK1/2 cascade is the most widely investigated. Thus far, the majority of studies have reported a positive correlation between the overactivation of ERK and the development of chemoresistance in numerous types of cancer cells (36-38). Certain studies have suggested that modulation of ERK activation may be a novel method in reversing MDR (40,41). Our previous study also demonstrated that ERK1/2 activity is upregulated in MDR HCC cells (26). As determined by these findings, inhibitors of the ERK/MAPK signaling pathway have been suggested to reverse MDR in HCC cells. In the present study, the upstream proteins, RAF and MEK, key proteins in the RAS/RAF/MEK/ERK cascade, were selected as the targets of inhibition. The results revealed that sorafenib and PD98059, which inhibit RAF and MEK kinases, respectively, downregulated the pERK1/2 levels without affecting the levels of total ERK1/2. The results of the cell viability assays demonstrated that sorafenib and PD98059 reduced the ADM IC₅₀ values in the SMMC7721/ADM and BEL7402/ADM cells, indicating that the two inhibitors reverse the resistance of HCC cells to ADM. Together, these results suggest the possibility of using the inhibitors of the ERK/MAPK signaling pathway as MDR reversal agents, thus providing evidence for the use of these inhibitors in combination with traditional chemotherapeutic drugs in treating HCC patients.

CsA, an inhibitor first used to analyze MDR reversal, enhances the apoptosis in tumor cells induced by chemotherapeutics through increasing the intracellular drug concentration. The MDR reversal mechanism of CsA possibly occurs through inhibiting the pump function of p-gp (42,43). In the present study, CsA upregulated, but did not downregulate, the expression of pERK1/2 in the HCC MDR cells. These results indicate that the downregulation of pERK1/2 was not involved in the reversal function of CsA, suggesting that the inhibition of the ERK/MAPK signaling pathway is not the only method to reverse MDR in HCC cells. In addition to leukocytes, CsA exerts potent effects on a number of distinct types of cells

and thus, regulates disparate biological functions (44-48). Furthermore, evidence is emerging that CsA regulates cell proliferation and invasion through ERK (44,49-51). Therefore, the increased pERK1/2 levels observed may be involved in certain other CsA effects in HCC cells. CsA treatment may therefore render cells in a state of stress, thus resulting in the upregulation of pERK1/2 through negative feedback.

The combined application of various chemotherapeutics is one method for mitigating drug resistance in classic chemotherapy (52). If the signaling pathway that exerts a predominant role in the growth tumor of a particular tumor becomes clear prior to the patient accepting therapy, the inhibitors of the corresponding signaling pathway may be pointedly selected to raise the effectiveness of chemotherapy. All results from the present study indicate that inhibition of ERK/MAPK signaling pathway activity may indeed reverse MDR in HCC cells, thus providing evidence for the use of ERK/MAPK signaling pathway inhibitors combined with traditional drugs in treating HCC. In addition, downregulation of the ERK/MAPK signaling pathway activity was not found to be involved in the CsA reversal function, which indicates that inhibiting ERK/MAPK signaling pathway activity is not a unique method to reverse MDR in HCC cells.

References

1. Tang S, Bao H, Zhang Y, *et al*: 14-3-3epsilon mediates the cell fate decision-making pathways in response of hepatocellular carcinoma to Bleomycin-induced DNA damage. *PLoS One* 8: e55268, 2013.
2. Zhong X, Xiong M, Meng X and Gong R: Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. *J Exp Clin Cancer Res* 29: 115, 2010.
3. Zhang Z, Zhou X, Shen H, Wang D and Wang Y: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. *BMC Med* 7: 41, 2009.
4. Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? *Oncologist* 11: 790-800, 2006.
5. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T and Okazaki K: The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. *Int J Oncol* 31: 1465-1472, 2007.
6. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2: 48-58, 2002.
7. List AF, Kopecky KJ, Willman CL, *et al*: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. *Blood* 98: 3212-3220, 2001.
8. Yamamoto K, Kikuchi Y, Kudoh K and Nagata I: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. *J Cancer Res Clin Oncol* 126: 168-172, 2000.
9. Holmström TH, Tran SE, Johnson VL, *et al*: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. *Mol Cell Biol* 19: 5991-6002, 1999.
10. Cowley GP and Smith ME: Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. *Int J Cancer* 60: 325-329, 1995.
11. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. *J Cell Sci* 117: 4619-4628, 2004.
12. Mansour SJ, Matten WT, Hermann AS, *et al*: Transformation of mammalian cells by constitutively active MAP kinase kinase. *Science* 265: 966-970, 1994.
13. Mansour SJ, Resing KA, Candi JM, *et al*: Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. *J Biochem* 116: 304-314, 1994.

14. Sturgill TW, Ray LB, Erikson E and Maller JL: Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. *Nature* 334: 715-718, 1988.
15. Boulton TG, Nye SH, Robbins DJ, *et al*: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. *Cell* 65: 663-675, 1991.
16. Seger R and Krebs EG: The MAPK signaling cascade. *FASEB J* 9: 726-735, 1995.
17. Hibi M, Lin A, Smeal T, Minden A and Karin M: Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. *Genes Dev* 7: 2135-2148, 1993.
18. Kyriakis JM, Banerjee P, Nikolakaki E, *et al*: The stress-activated protein kinase subfamily of c-Jun kinases. *Nature* 369: 156-160, 1994.
19. Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. *Science* 265: 808-811, 1994.
20. Freshney NW, Rawlinson L, Guesdon F, *et al*: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. *Cell* 78: 1039-1049, 1994.
21. Rouse J, Cohen P, Trigon S, *et al*: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. *Cell* 78: 1027-1037, 1994.
22. Lee JC, Laydon JT, McDonnell PC, *et al*: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature* 372: 739-746, 1994.
23. Zhou G, Bao ZQ and Dixon JE: Components of a new human protein kinase signal transduction pathway. *J Biol Chem* 270: 12665-12669, 1995.
24. Lee JD, Ulevitch RJ and Han J: Primary structure of BMK1: a new mammalian map kinase. *Biochem Biophys Res Commun* 213: 715-724, 1995.
25. Kohno M, Tanimura S and Ozaki K: Targeting the extracellular signal-regulated kinase pathway in cancer therapy. *Biol Pharm Bull* 34: 1781-1784, 2011.
26. Yan X, Ruan W, Wang X, *et al*: The effects of multidrug resistance on cell proliferation, apoptosis and invasion activity and the expression of mitogen-activated protein kinase in human hepatocellular cancer cells. *Zhong Liu* 32: 507-515, 2012 (In Chinese).
27. Philip PA, Mahoney MR, Allmer C, *et al*: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. *J Clin Oncol* 23: 6657-6663, 2005.
28. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 132: 2557-2576, 2007.
29. Geng W, Ng KT, Sun CK, *et al*: The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. *PLoS One* 6: e27362, 2011.
30. Sheng Long, Xiong Maoming: Progress in primary liver cancer resistant MDR reversal of Hepatobiliary Surgery 20: 236-238, 2012.
31. Dai CL and Fu LW: The development of the reversal of the tumor multidrug resistance. *Chin Pharm Bulletin* 21: 513-8, 2005.
32. Pétriz J, Sánchez J, Bertrán J and García-López J: Comparative effect of verapamil, cyclosporin A and SDZ PSC 833 on rhodamine 123 transport and cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotein. *Anticancer Drugs* 8: 869-875, 1997.
33. Dreuw A, Hermanns HM, Heise R, *et al*: Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. *J Invest Dermatol* 124: 28-37, 2005.
34. Imai Y, Ohmori K, Yasuda S, *et al*: Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase. *Cancer Sci* 100: 1118-1127, 2009.
35. Gómez-Martínez A, García-Morales P, Carrato A, *et al*: Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. *Mol Cancer Res* 5: 641-653, 2007.
36. Guan J, Chen XP, Zhu H, *et al*: Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. *World J Gastroenterol* 10: 3522-3527, 2004.
37. Zhu H, Chen XP, Luo SF, *et al*: The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma. *Zhonghua Wai Ke Za Zhi* 45: 917-920, 2007 (In Chinese).
38. Kisucká J, Barancík M, Boháčová V and Breier A: Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. *Gen Physiol Biophys* 20: 439-444, 2001.
39. Chen B, Jin F, Lu P, *et al*: Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803. *World J Gastroenterol* 10: 795-799, 2004.
40. Li Y, Li S, Han Y, *et al*: Celebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. *Eur J Pharmacol* 591: 252-258, 2008.
41. Hu Y, Bally M, Dragowska WH and Mayer L: Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. *Mol Cancer Ther* 2: 641-649, 2003.
42. Anglicheau D, Pallet N, Rabant M, *et al*: Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. *Kidney Int* 70: 1019-1025, 2006.
43. Tanaka S, Hirano T, Saito T, Wakata N and Oka K: P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. *Biol Pharm Bull* 30: 291-296, 2007.
44. Alvarez-Arroyo MV, Yagüe S, Wenger RM, *et al*: Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. *Circ Res* 91: 202-209, 2002.
45. Robida AM, Xu K, Ellington ML and Murphy TJ: Cyclosporin A selectively inhibits mitogen-induced cyclooxygenase-2 gene transcription in vascular smooth muscle cells. *Mol Pharmacol* 58: 701-708, 2000.
46. Chen HW, Chien CT, Yu SL, Lee YT and Chen WJ: Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70. *Br J Pharmacol* 137: 771-781, 2002.
47. Kiely B, Feldman G and Ryan MP: Modulation of renal epithelial barrier function by mitogen-activated protein kinases (MAPKs): mechanism of cyclosporine A-induced increase in transepithelial resistance. *Kidney Int* 63: 908-916, 2003.
48. Hojo M, Morimoto T, Maluccio M, *et al*: Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature* 397: 530-534, 1999.
49. Paslaru L, Trigon S, Kuhlmann M and Morange M: MAP kinase activation by cyclosporine A. *Biochem Biophys Res Commun* 236: 599-603, 1997.
50. Du MR, Zhou WH, Yan FT, *et al*: Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. *Hum Reprod* 22: 2528-2537, 2007.
51. Zhou WH, Du MR, Dong L, *et al*: Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway. *Hum Reprod* 22: 2743-2750, 2007.
52. Cen J and Li YM: Combination therapy on multidrug-resistance tumor. *World Notes Antibiotics* 5: 224-228, 2009.